Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care

被引：7

作者：

Bell, Jill A. ^{[1
]}

Galaznik, Aaron ^{[1
]}

Blazer, Marlo ^{[2
]}

Farrelly, Eileen ^{[2
]}

Ogbonnaya, Augustina ^{[2
]}

Raju, Aditya ^{[2
]}

Eaddy, Michael ^{[2
]}

Fram, Robert J. ^{[1
,2
]}

Faller, Douglas V. ^{[1
]}

机构：

[1] Millennium Pharmaceut Inc, Cambridge, MA USA

[2] Xcenda LLC, Palm Harbor, FL USA

来源：

LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 01期

关键词：

Higher-risk myelodysplastic syndrome; transfusion-free interval; survival; PROGNOSTIC SCORING SYSTEM; LEUKEMIA GROUP; PHASE-III; AZACITIDINE; IMPACT; MDS; CLASSIFICATION; DECITABINE; CANCER; LIFE;

D O I：

10.1080/10428194.2018.1464155

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Most higher-risk myelodysplastic syndrome (HR-MDS) patients will become transfusion-dependent, leading to potential complications, including infections or end-organ dysfunction. Data correlating achievement of transfusion-free intervals (TFIs) during first-line therapy (1LT) with survival are sparse. We evaluated HR-MDS patients receiving 1LT diagnosed from 1/1/2008 to 7/31/2015 and the impact of a TFI (>= 60-day interval without transfusions) on progression-free and overall survival (PFS, OS) using Cox proportional-hazard models. Two hundred and twenty-nine HR-MDS patients received 1LT; overall, median PFS/OS were 8.4 months and 14.7 months, respectively. Two-year PFS/OS were 22.3% and 34.6%, respectively. Median PFS/OS were longer for patients with vs. without a TFI (16.9 vs. 6.1 months and 26.1 vs. 11.8 months, respectively; p < .01 [both]). Two-year PFS (43.0% vs. 3.9%; p < .01) and 2-year OS (51.8% vs. 22.5%; p < .01) were also longer in patients with a TFI vs. not. Achievement of a TFI during 1LT appears to positively affect PFS and OS in HR-MDS patients.

引用

页码：49 / 59

页数：11

共 27 条

[1] WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome:: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) [J].

Alessandrino, Emilio Paolo ;

Della Porta, Matteo Giovanni ;

Bacigalupo, Andrea ;

Van Lint, Maria Teresa ;

Falda, Michele ;

Onida, Francesco ;

Bernardi, Massimo ;

Iori, Anna Paola ;

Rambaldi, Alessandro ;

Cerretti, Raffaella ;

Marenco, Paola ;

Pioltelli, Pietro ;

Malcovati, Luca ;

Pascutto, Cristiana ;

Oneto, Rosi ;

Fanin, Renato ;

Bosi, Alberto ;

Levis, A. ;

Rambaldi, A. ;

Bandini, G. ;

Casini, M. ;

Rossi, G. ;

Angelucci, E. ;

Baronciani, D. ;

La Nasa, G. ;

Milone, G. ;

Mordini, N. ;

Guidi, S. ;

Bosi, A. ;

Bacigalupo, A. ;

Van Lint, M. T. ;

Corradini, P. ;

Milani, R. ;

Morra, E. ;

Marenco, P. ;

Deliliers, G. Lambretenghi ;

Onida, F. ;

Ciceri, F. ;

Bernardi, M. ;

Castagna, L. ;

Narni, F. ;

Pioltelli, P. ;

Selleri, Carmine ;

Scime, R. ;

Iannitto, E. ;

Musso, M. ;

Alessandrino, E. P. ;

Locatelli, F. ;

Martelli, F. ;

Visani, G. .

BLOOD, 2008, 112 (03) :895-902

[2] Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry [J].

Bernal, T. ;

Martinez-Camblor, P. ;

Sanchez-Garcia, J. ;

de Paz, R. ;

Luno, E. ;

Nomdedeu, B. ;

Ardanaz, M. T. ;

Pedro, C. ;

Amigo, M. L. ;

Xicoy, B. ;

del Canizo, C. ;

Tormo, M. ;

Bargay, J. ;

Valcarcel, D. ;

Brunet, S. ;

Benlloch, L. ;

Sanz, G. .

LEUKEMIA, 2015, 29 (09) :1875-1881

[3]

Brechignac S, 2004, BLOOD, V104, p263B

[4]

Cazzola M, 1998, HAEMATOLOGICA, V83, P910

[5] Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes [J].

DeZern, Amy E. ;

Binder, Gary ;

Rizvi, Syed ;

Corvino, Frank A. ;

Arikian, Steven R. ;

Surinach, Andy ;

Lee, Jianyi ;

Smith, B. Douglas .

LEUKEMIA & LYMPHOMA, 2017, 58 (11) :2649-2656

[6] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry [J].

Dinmohamed, A. G. ;

van Norden, Y. ;

Visser, O. ;

Posthuma, E. F. M. ;

Huijgens, P. C. ;

Sonneveld, P. ;

van de Loosdrecht, A. A. ;

Jongen-Lavrencic, M. .

LEUKEMIA, 2015, 29 (12) :2449-2451

[7] Progression of myelodysplasia to acute lymphoblastic leukaemia: Implications for disease biology [J].

Disperati, P ;

Ichim, CV ;

Tkachuk, D ;

Chun, K ;

Schuh, AC ;

Wells, RA .

LEUKEMIA RESEARCH, 2006, 30 (02) :233-239

[8] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Finelli, Carlo ;

Giagounidis, Aristoteles ;

Schoch, Robert ;

Gattermann, Norbert ;

Sanz, Guillermo ;

List, Alan ;

Gore, Steven D. ;

Seymour, John F. ;

Bennett, John M. ;

Byrd, John ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

LANCET ONCOLOGY, 2009, 10 (03) :223-232

[9] International scoring system for evaluating prognosis in myelodysplastic syndromes [J].

Greenberg, P ;

Cox, C ;

LeBeau, MM ;

Fenaux, P ;

Morel, P ;

Sanz, G ;

Sanz, M ;

Vallespi, T ;

Hamblin, T ;

Oscier, D ;

Ohyashiki, K ;

Toyama, K ;

Aul, C ;

Mufti, G ;

Bennett, J .

BLOOD, 1997, 89 (06) :2079-2088

[10]

Greenberg P., 2000, Hematology: Basic Principles and Practice, V3rd, P1106

← 1 2 3 →